Hidradenitis suppurativa – biologic therapy and other available treatment options

Lipa, Katarzyna; Zając, Natalia; Witkowski², Grzegorz; Ciechanowicz, Piotr; Wiszniewski, Kacper; Szymańska, Elżbieta; Walecka, Irena

Hidradenitis suppurativa – biologic therapy and other available treatment options

Document detail

ID

oai:pubmedcentral.nih.gov:1048...

Topic

Review Paper

Author

Lipa, Katarzyna Zając, Natalia Witkowski², Grzegorz Ciechanowicz, Piotr Wiszniewski, Kacper Szymańska, Elżbieta Walecka, Irena

Langue

Editor

Termedia Publishing House

Year

2022

listing date

8/16/2024

Keywords

biologic therapy treatment hs

Metrics

Abstract

Hidradenitis suppurativa (HS) is a chronic recurrent inflammatory skin disease which is characterized by painful, recurrent nodules and abscesses.

The overall prevalence of HS is estimated to be 11 per 100 000 individuals in the United States and 4% of the world’s population.

Women are three times more affected than men, especially patients between 18 and 29 years.

Similarly to acne vulgaris, HS is primarily associated with follicular occlusion, which results from a number of biological processes, including follicular epithelial hyperplasia and hyperkeratinization.

There are numerous available treatment options for cutaneous lesions in the course of HS.

A combination of conservative therapy and appropriate surgical treatment conducted by an experienced surgeon ensures the best possible clinical outcomes.

Presently, biologic therapy is the most effective pharmacological treatment in patients with a moderate-to-severe course of the disease.

Numerous ongoing clinical trials provide hope for greater availability of new biologic therapy methods.

Lipa, Katarzyna,Zając, Natalia,Witkowski², Grzegorz,Ciechanowicz, Piotr,Wiszniewski, Kacper,Szymańska, Elżbieta,Walecka, Irena, 2022, Hidradenitis suppurativa – biologic therapy and other available treatment options, Termedia Publishing House